Evidence map›Paper›PMID 42782869›Full record

ReviewCurrent oncology (Toronto, Ont.)2026

Cellular and Immunotherapy for Pediatric Brain Tumors: A Primer.

Irem Yenidogan, Nirav Thacker, Anirban Das, Magimairajan Issai Vanan

Abstract readReview
In one paragraph

Review in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Irem YenidoganDivision of Hematology-Oncology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
Nirav ThackerHematology-Oncology, Children's Hospital of Eastern Ontario, Ottawa, ON K1H 8L1, Canada.
Anirban DasDivision of Hematology-Oncology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
Magimairajan Issai VananDivision of Hematology-Oncology, Cancer Care Manitoba, Winnipeg, MN R3E 0V9, Canada.ORCID 0000-0003-2015-0615

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain tumors are the most common solid malignancies in children and the leading cause of cancer-related mortality in this age group. Cancer immunotherapy has shown a lot of promise in the treatment of both adult and pediatric cancers. In this review, we summarize the use of immunotherapies in the treatment of pediatric brain tumors with special emphasis on CAR T cells, Immune checkpoint inhibitors and oncolytic viral therapy.

Indexed as

Brain NeoplasmsImmunotherapyChildHumansImmunotherapy, AdoptiveOncolytic VirotherapyCAR T cellsimmune checkpoint inhibitionimmunotherapyoncolytic viruses

Identifiers

PMID42782869
PMCPMC13605142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.